Acute effect of add-on therapy with tofogliflozin, a sodium glucose co-transporter 2 inhibitor, on 24-hours glucose profile and glycaemic variability evaluated by continuous glucose monitoring in patients with type 2 diabetes receiving dipeptidyl peptidase-4 inhibitors.
Toshie IijimaSoichiro HosonumaHidetaka KuraiHayato KajitaniShintaro SakuraiTakuya TomaruTeruo JojimaIsao UsuiYoshimasa AsoPublished in: International journal of clinical practice (2021)
Add-on therapy with tofogliflozin to DPP-4 inhibitors acutely reduces 24-hours glucose levels and improves glycaemic variability in patients with type 2 diabetes.